CRCNJ is now enrolling patients in blüm, a Phase III clinical trial for CM-AT, a potential first-in-class treatment for autism. CM-AT is developed by Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases.
CM-AT is based on Curemark’s recent research that showed enzyme deficiencies in some autistic children result in an inability to digest protein. The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.
CRCNJ is one of over 20 sites across the country conducting the blüm Phase III clinical trial of CM-AT in autism.
STUDY COMPLETED, CLOSED FOR ENROLLMENT.
NeurAbilities (Voorhees, NJ) was awarded a two-year grant to investigate for genetic abnormalities in those with Autism Spectrum Disorders (ASD) associated with intellectual disabilities and/or epilepsy, and determine their clinical manifestations. Findings from this research project may discover new biological causes of ASDs and associated complications, as well as assist clinicians in determining treatments targeting mechanisms of disease rather than symptoms. The Center for Neurological and Neurodevelopmental Health (CNNH) will lead this project, with three collaborating institutions: Courtagen Life Sciences (Woburn, Massachusetts), Coriell Institute for Medical Research (Camden, NJ), and the Mitochondrial Disease Laboratory of St. Christopher’s Hospital for Children (Philadelphia, PA). These four specialized and innovative organizations will work collaboratively to investigate how certain genetic variations are associated with impairments in brain energy production and function, and can subsequently cause ASDs and/or lead to complications of ASDs, such as epilepsy, gastrointestinal problems, and serious behavioral disturbances.
Children and adults with Autism Spectrum Disorders and associated Intellectual Disabilities and/or Epilepsy between the ages of 6 and 30 years of age are eligible to participate in the study. Comprehensive clinical assessments include the following:
• Specialized Genetic Testing
• Dense Array Electroencephalographic (“brain wave”) Testing
• Neurological and Medical Evaluation
• Neuropsychological Testing
• Functional Behavioral Analysis
• Sleep Assessment
• Laboratory Testing
Help increase our knowledge of autism spectrum conditions and consider participation in this study.
This clinical research is funded in part by The New Jersey Governor’s Council for Medical Research and Treatment of Autism and the New Jersey Department of Health.
ONGOING STUDY, CLOSED FOR ENROLLMENT.
CRCNJ is conducting various clinical trials that are not yet listed on this page, please contact us to find out if there is a clinical trial right for you.